Inhibition of tumor cell growthin vitro andin vivo by 2-methyl 9-hydroxyellipticinium entrapped within phospholipid vesicles
- 1 July 1986
- journal article
- research article
- Published by Wiley in Biopharmaceutics & Drug Disposition
- Vol. 7 (4) , 357-371
- https://doi.org/10.1002/bdd.2510070406
Abstract
Encapsulation in liposomes of the antitumoral drug 2‐methyl 9‐hydroxyellipticinium and the consequences of its cytoxicity in vitro on L1210 leukemia cells and on its antitumoral activity in vivo on leukemic mice inoculated with L1210 cells are described. Provided the drugs is dissolved in the buffer below its critical micelle concentration (10−4M), it can be encapsulated in lipid vesicles with a very good yield in the form of a very stable combination with the lipids. The in vitro experiments show that 2‐CH3 9‐OH‐ellipticinium is less cytotoxic against L1210 cells when entrapped than when free in solution. The in vivo experiments on tumor‐bearing mice show that encapsulation of the drug reduces its toxicity. Encapsulation maintains the antitumoral activity of the drug or increases it if the leukemia is delayed (104 cells injected per mouse instead of 105 cells per mouse).Keywords
This publication has 26 references indexed in Scilit:
- Unexpected regiospecific alkylation of the antitumor agent N2-methyl-9-hydroxyellipticinium acetate with N, O or S donorsTetrahedron Letters, 1983
- Metabolism of the anti-tumour drugsN2-methyl-9-hydroxyellipticinium acetate (NSC 264137) andN2-methyl-9-hydroxyolivacinium acetate in the rat: preliminary identification of biliary 9-(O)-glucuronide and 10-(S)-glutathione conjugatesXenobiotica, 1983
- Bioactivation of the antitumor drugs 9-hydroxyellipticine and derivatives by a peroxidase-hydrogen peroxide systemJournal of Medicinal Chemistry, 1981
- Intracellular penetration of liposomes containing a water insoluble antimitotic drug in L1210 cellsPublished by Elsevier ,1980
- Interactions between ellipticine and some derivatives and phospholipids in model membranesFEBS Letters, 1979
- Preliminary trial of 9-hydroxy-2-methyl ellipticinium (NSC 264-137) in advanced human cancersPublished by Elsevier ,1978
- A New Antitumoral Agent: 9-Hydroxyellipticine. Possibility of a Rational Design of Anticancerous Drugs in the Series of DNA Intercalating DrugsProceedings of the National Academy of Sciences, 1974
- A new DNA intercalating drug: Methoxy‐9‐ellipticineFEBS Letters, 1971
- The detection of oxidation in liposome preparationsBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1970
- Synthesis of the tumour-inhibitory alkaloids, ellipticine, 9-methoxyellipticine, and related pyrido[4,3-b]carbazolesAustralian Journal of Chemistry, 1967